Astec Lifesciences Ltd's Q3FY25 Quarter Results
- 28 Jan 2025
Result Summary
- Astec Lifesciences Ltd reported a 4.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 85.2%.
- Its expenses for the quarter were down by 13.1% QoQ and up 44.1% YoY.
- The net profit increased 4.7% QoQ and increased 66.0% YoY.
- The earnings per share (EPS) of Astec Lifesciences Ltd declined at 20.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 95.77 | 100.54 | 51.70 | -4.7% | 85.2% |
Total Expenses | 120.92 | 139.08 | 83.92 | -13.1% | 44.1% |
Profit Before Tax | -25.15 | -38.54 | -32.22 | -34.7% | -21.9% |
Tax | 15.22 | 0.01 | -7.89 | 152100.0% | -292.9% |
Profit After Tax | -40.37 | -38.55 | -24.32 | 4.7% | 66.0% |
Earnings Per Share | -20.60 | -19.70 | -12.40 | 4.6% | 66.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Astec Lifesciences Ltd is a prominent player in the agrochemical industry, primarily focusing on the production and sale of agrochemical products. The company specializes in manufacturing a range of fungicides, herbicides, and insecticides that cater to the needs of the agricultural sector. It operates within a market characterized by rapid advancements and significant regulatory considerations. As of the latest data available, there are no specific recent major developments disclosed, such as mergers, acquisitions, or significant product launches. The company is known for its focus on research and development to enhance product efficacy and sustainability.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Astec Lifesciences Ltd reported a total income of ₹95.77 crores. This represents a decrease of 4.7% on a quarter-over-quarter (QoQ) basis when compared to the previous quarter (Q2FY25), where the total income was ₹100.54 crores. However, there is a significant year-over-year (YoY) increase of 85.2% compared to the same quarter in the previous fiscal year (Q3FY24), which recorded a total income of ₹51.70 crores. This substantial increase on a yearly basis indicates a strong revenue growth trajectory over the past year, reflecting the company's ability to enhance its market presence and demand for its products.
Profitability
In terms of profitability, Astec Lifesciences Ltd posted a loss before tax of ₹25.15 crores in Q3FY25. This represents a notable improvement of 34.7% QoQ compared to the previous quarter's loss of ₹38.54 crores. On a YoY basis, the loss before tax decreased by 21.9% from a loss of ₹32.22 crores in Q3FY24. Despite these improvements, the company incurred a tax expense of ₹15.22 crores in Q3FY25, a significant change from the negligible tax of ₹0.01 crores in Q2FY25 and a tax benefit of ₹7.89 crores in Q3FY24. Consequently, the profit after tax stood at a loss of ₹40.37 crores, indicating a slight QoQ deterioration of 4.7% from the previous quarter's loss of ₹38.55 crores. The YoY comparison shows a 66.0% increase in losses from Q3FY24's loss of ₹24.32 crores.
Operating Metrics
The earnings per share (EPS) for Q3FY25 was reported at a negative ₹20.60, marking a QoQ decline of 4.6% from an EPS of negative ₹19.70 in Q2FY25. On a YoY basis, the EPS deteriorated by 66.1% from a negative ₹12.40 in Q3FY24. This trend highlights the ongoing challenges in translating revenue growth into profitability. Despite the reduction in total expenses from ₹139.08 crores in Q2FY25 to ₹120.92 crores in Q3FY25, a decrease of 13.1%, the company has not yet achieved positive earnings. Compared to Q3FY24, total expenses increased by 44.1% from ₹83.92 crores, reflecting an expansion in operational activities or cost structures over the past year. These operating metrics present a complex picture of the company's financial health, emphasizing areas for further strategic focus and operational efficiency.
